Category: Pharmaceuticals

Ticagrelor Monotherapy After PCI Shows Promise: Lower Bleeding Risk, No Increased Revascularization

A recent analysis of the TWILIGHT trial reveals that ticagrelor monotherapy after three months of dual antiplatelet therapy (DAPT) does not increase the risk of revascularization after percutaneous coronary intervention (PCI). In fact, monotherapy with ticagrelor shows a lower bleeding risk compared to continued DAPT. These findings provide insights into the potential benefits of ticagrelor monotherapy as a treatment strategy after PCI.

Read More